Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company dedicated to discovering, developing, and delivering curative therapies for heart disease. Founded by leading cardiovascular scientists, the company aims to change the treatment paradigm for heart disease through innovative platforms including Gene Therapy, Cellular Regeneration, and Precision Medicine. Their mission is to improve and extend the lives of millions affected by heart disease.
Industries
Nr. of Employees
medium (51-250)
Tenaya Therapeutics
171 Oyster Point Blvd., Suite 500, South San Francisco, CA 94080
Patents
Products
AAV-mediated MYBPC3 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy
A one-time systemic AAV gene therapy approach to deliver a functional MYBPC3 coding cassette to restore MYBPC3 protein levels and reverse disease features in MYBPC3-associated HCM; progressed through IND-enabling studies and entered Phase 1b clinical testing.
AAV-mediated PKP2 gene therapy for PKP2-associated ARVC
AAV gene therapy program designed to deliver functional PKP2 to prevent or reverse arrhythmogenic right ventricular cardiomyopathy in patients with PKP2 mutations; demonstrated prevention and reversal in murine models and received orphan designation.
AAV-mediated DWORF gene therapy for dilated cardiomyopathy
AAV approach to deliver the DWORF micropeptide to modulate the SERCA2a pathway and improve cardiac contractility in dilated cardiomyopathy; supported by preclinical proof-of-concept in multiple models.
Selective HDAC6 small-molecule inhibitors for HFpEF
Highly selective HDAC6 inhibitor series discovered using hiPSC-CM phenotypic screening and medicinal chemistry optimization; shown to improve diastolic function and reduce fibrosis and inflammation in preclinical HFpEF models and advanced to IND-enabling and early clinical studies.
AAV-based cardiac reprogramming therapy for post-myocardial infarction heart failure
Single-AAV delivery of a three-gene cocktail to reprogram resident cardiac fibroblasts into cardiomyocytes in vivo; shown to improve function in rat and porcine models.
In vivo gene editing programs for cardiomyopathies (discovery stage)
Preclinical gene editing development including prime editing and self-inactivating AAV gene editing constructs targeting specific cardiomyopathy mutations.
AAV-mediated MYBPC3 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy
A one-time systemic AAV gene therapy approach to deliver a functional MYBPC3 coding cassette to restore MYBPC3 protein levels and reverse disease features in MYBPC3-associated HCM; progressed through IND-enabling studies and entered Phase 1b clinical testing.
AAV-mediated PKP2 gene therapy for PKP2-associated ARVC
AAV gene therapy program designed to deliver functional PKP2 to prevent or reverse arrhythmogenic right ventricular cardiomyopathy in patients with PKP2 mutations; demonstrated prevention and reversal in murine models and received orphan designation.
AAV-mediated DWORF gene therapy for dilated cardiomyopathy
AAV approach to deliver the DWORF micropeptide to modulate the SERCA2a pathway and improve cardiac contractility in dilated cardiomyopathy; supported by preclinical proof-of-concept in multiple models.
Selective HDAC6 small-molecule inhibitors for HFpEF
Highly selective HDAC6 inhibitor series discovered using hiPSC-CM phenotypic screening and medicinal chemistry optimization; shown to improve diastolic function and reduce fibrosis and inflammation in preclinical HFpEF models and advanced to IND-enabling and early clinical studies.
AAV-based cardiac reprogramming therapy for post-myocardial infarction heart failure
Single-AAV delivery of a three-gene cocktail to reprogram resident cardiac fibroblasts into cardiomyocytes in vivo; shown to improve function in rat and porcine models.
In vivo gene editing programs for cardiomyopathies (discovery stage)
Preclinical gene editing development including prime editing and self-inactivating AAV gene editing constructs targeting specific cardiomyopathy mutations.
Services
Collaborative discovery and preclinical development partnerships for cardiac therapies, including access to disease models, capsid engineering, and co-development opportunities.
Collaborative discovery and preclinical development partnerships for cardiac therapies, including access to disease models, capsid engineering, and co-development opportunities.
Expertise Areas
- Cardiac gene therapy development
- AAV capsid discovery and engineering
- Cellular reprogramming for cardiac regeneration
- iPSC-derived cardiomyocyte disease modeling
Key Technologies
- Adeno-associated virus (AAV) vectors
- Capsid engineering and directed evolution
- HEK293 transient transfection production
- Sf9 / baculovirus suspension production
News & Updates
Announcement of inducement grants following NASDAQ listing.
Presentation of advancements in capsid engineering, gene editing, and manufacturing research.
Financial results and updates on clinical progress and business strategy.
Funding to support clinical development and manufacturing capabilities.
Preclinical data supporting gene therapy and regenerative approaches.
Discussion on developing cell and gene therapies for cardiovascular diseases.
Announcement of inducement grants following NASDAQ listing.
Presentation of advancements in capsid engineering, gene editing, and manufacturing research.
Financial results and updates on clinical progress and business strategy.
Funding to support clinical development and manufacturing capabilities.
Preclinical data supporting gene therapy and regenerative approaches.
Discussion on developing cell and gene therapies for cardiovascular diseases.